BRCA1 and ductal breast carcinoma in situ: Chapman et al. [3] examined by enzyme-linked immunosorbent assay (ELISA) the presence of AAbs to each of the following seven TAAs: p53, c-myc, HER2, NY-ESO-1, BRCA1, BRCA2, and MUC1 in the sera of 97 breast carcinoma patients, 40 ductal carcinoma in situ patients, and 94 normal controls.